Table 1.
Clinical characteristics of the breast cancer patients in this study.
HR+/HER2– (n = 410) No. (%) | |
---|---|
Median age (min–max) (years) | 47.3 (25.2–80.5) |
Age (years) | |
<50 | 241 (58.8%) |
≥50 | 169 (41.2%) |
Tumor size (cm) | |
≤ 2 | 183 (44.6%) |
2-5 | 204 (49.8%) |
>5 | 23 (5.6%) |
Lymph node status | |
Negative | 203 (49.5%) |
Positive | 207 (50.5%) |
pN | |
0 | 203 (49.5%) |
1 | 112 (27.3%) |
2 | 51 (12.4%) |
3 | 44 (10.7%) |
Pathologic stage | |
I | 113 (27.6%) |
II | 197 (48.0%) |
III | 100 (24.4%) |
Histologic grade | |
1 | 77 (18.8%) |
2 | 199 (48.5%) |
3 | 123 (30%) |
Unknown | 11 (2.7%) |
Nuclear grade | |
1 | 60 (14.6%) |
2 | 256 (62.4%) |
3 | 81 (19.8%) |
Unknown | 13 (3.2%) |
Hormone therapy | |
No | 21 (5.1%) |
Yes | 379 (92.4%) |
Unknown | 10 (2.4%) |
Chemotherapy | |
No | 68 (16.6%) |
Yes | 342 (83.4%) |
Unknown | 0 (0.0%) |
Radiotherapy | |
No | 162 (39.5%) |
Yes | 247 (60.2%) |
Unknown | 1 (0.2%) |
NPI | |
1 | 113 (27.6%) |
2 | 113 (27.6%) |
3 | 113 (27.6%) |
4 | 58 (14.1%) |
Unknown | 13 (3.2%) |
HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; pN, pathologic nodal status; NPI, Nottingham prognostic index.